rabeprazole / Generic mfg. - LARVOL DELTA

Post-translational modifications of triosephosphate isomerase reveal metabolic vulnerabilities in T-ALL. Effect of combining dichloroacetic acid and the PPI rabeprazole. (PubMed, Biochem J) - "Finally, combined dichloroacetate-rabeprazole treatment induced extensive apoptotic death in Jurkat cells while sparing normal lymphocytes. These findings identify post-translational modifications-bearing TPI isoforms as selective metabolic vulnerabilities in Jurkat cells and support the potential repurposing of thiol-modifying agents, particularly, rabeprazole, as targeted antileukemic strategies."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma

Efficacy of vonoprazan fumarate in the treatment of peptic ulcers (ChiCTR) - P=N/A | N=600 | Completed | Sponsor: Xiamen Humanity hospital; Xiamen Humanity hospital

New trial • Gastroenterology • Peptic Ulcer

Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy (clinicaltrials.gov) - P=N/A | N=552 | Recruiting | Sponsor: Kaohsiung Medical University

New trial • Infectious Disease

The Efficacy and Safety of Anaprazole Quadruple Therapy Versus Rabeprazole Quadruple Therapy for Helicobacter pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study (ChiCTR) - P=N/A | N=220 | Not yet recruiting | Sponsor: NanJing First Hospital; NanJing First Hospital

New trial • Gastrointestinal Disorder • Infectious Disease

Analysis of the efficacy and safety of magaldrate granules quadruple therapy in the treatment of Helicobacter pylori infection (PubMed, Zhonghua Yi Xue Za Zhi) - "No statistically significant differences were found in the incidence rates of these adverse events between Group A and Control Group, or Group B and Control Group (all P>0.05). The quadruple therapy combining magaldrate granules with rabeprazole, amoxicillin, and clarithromycin demonstrates good Hp eradication efficacy and high safety."

Journal • Gastrointestinal Disorder • Infectious Disease • Pain

Adjunctive probiotic therapy sustains symptom relief in gastroesophageal reflux disease through gut microbiome-metabolome remodeling. (PubMed, mSystems) - P=N/A | "The study aimed to evaluate the efficacy of a multi-strain probiotic (Lihuo) with rabeprazole in GERD and its impact on gut microbiota and metabolome...Strong correlations linked microbial shifts to metabolic and clinical improvements. This study demonstrates that adjunctive probiotic therapy enhances symptom control and supports microbial-metabolic homeostasis in GERD.CLINICAL TRIALSThis study is registered with the Chinese Clinial Trial Registry as ChiCTR2000038409."

Clinical • Journal • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder

Assessment of diverse proton pump inhibitor combined with bismuth quadruple regimens and risk factors for Helicobacter pylori eradication in China: A retrospective single-center study. (PubMed, Arab J Gastroenterol) - "The eradication rates across various PPI-based quadruple regimens were comparable; however, the regimen comprising amoxicillin and clarithromycin demonstrated low efficacy and is not advised in settings with high clarithromycin resistance. Among the effective therapeutic regimens, the esomeprazole-based regimen exhibited a slightly higher eradication rate."

Journal • Retrospective data • Infectious Disease

A novel extracellular vesicle-engineered immunotherapy drug for Her2+ breast cancer. (PubMed, J Adv Res) - "Trastuzumab profoundly improves outcomes of Her2+ breast cancer (BC) patients, but eventual drug resistance is inevitable...Moreover, EVs/Her2-scFv loaded with rabeprazole (EVs/Her2-scFv/Rabe) effectively improve tumor immunosuppressive microenvironment and abnormal vasculature of Her2+ BC by reducing tumor EVs...Besides, EVs/Her2-scFv/CXCL9/Rabe are low-immunogenic with biosafety. Altogether, EVs/Her2-scFv/CXCL9/Rabe hold high potential in Her2+ BC therapy."

Journal • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CD8 • CXCL9 • HER-2

Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication (clinicaltrials.gov) - P=N/A | N=390 | Recruiting | Sponsor: Kaohsiung Medical University | N=780 ➔ 390

Enrollment change • Infectious Disease

Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents: A Randomized Controlled Trial (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: China-Japan Friendship Hospital

New P1 trial • Gastroenterology

Risk of Depression Related to Use of Proton Pump Inhibitors and Tegoprazan: A Nationwide Cohort Study. (PubMed, J Korean Med Sci) - "In this national longitudinal study, PCAB users had a lower likelihood of developing depression than PPI users. Additional studies on the biological mechanism for the risk of depression and gastric acid suppressants are needed."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

A Vanished Association Between Proton Pump Inhibitors and Clostridioides Difficile Infection After Minimizing Bias. (PubMed, J Clin Med) - "Initial analysis revealed a significant PPI-CDI association (ROR = 2.36, 95% confidence interval (95%CI) 2.19 to 2.53; IC = 1.21, 95%CI 0.97 to 1.45), with CDI signals detected for five PPI agents, including pantoprazole, omeprazole, lansoprazole, rabeprazole, and dexlansoprazole. Age-stratified analyses demonstrated complete signal loss after antibacterial drug adjustment across all age groups. The current large-scale pharmacovigilance study indicated that the observed PPI-CDI association may be mediated predominantly by antibacterial drug co-exposure rather than PPI direct causation."

Journal • Infectious Disease • Renal Disease

A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Genentech, Inc.

New P1 trial

Rabeprazole attenuates fibrosis by modulating SMAD3 linker region phosphorylation. (PubMed, Biomed Rep) - "Overall, the present findings reveal a previously unrecognized antifibrotic activity of rabeprazole. These findings enriched the biological function of rabeprazole and highlight a novel regulatory mechanism underlying its antifibrotic activity."

Journal • Fibrosis • Immunology • Infectious Disease • COL1A1 • SMAD3

A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults. (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: Pfizer

New P1 trial

Development of Simple Fluorescence Spectrometry With Blue Emissive V2C MXene for Selective Detection of Rabeprazole Sodium in Pharmaceutical Samples. (PubMed, Luminescence) - "This work is also assessed in terms of its greenness and blueness using metrics like the Complex Green Analytical Procedure Index (GAPI) and the Blue Applicability Grade Index (BAGI) tools. Bringing together, V2C MXene FNPs could be admitted as a promising fluorescent probe for assaying R-Na in drug samples with justifiable accuracy and precision."

Journal

The Efficacy of Potassium-Competitive Acid Blocker Compared With Double Dose of Proton Pump Inhibitor in Patients With Refractory Gastro-Esophageal Reflux Disease: A Case-Control Study. (PubMed, Korean J Helicobacter Up Gastrointest Res) - "Double split doses of rabeprazole (20 mg) or tegoprazan (50 mg) were prescribed for 2 weeks, and the symptoms were subsequently evaluated. In patients with refractory GERD symptoms, PCAB therapy had effects corresponding to those of a double split dose of PPIs. PCAB therapy was therefore deemed superior to PPIs, especially in patients with abnormal AETs."

Journal • Gastroenterology • Gastroesophageal Reflux Disease

Analysis of infection-related adverse events induced by proton pump inhibitors based on the FAERS and JADER databases. (PubMed, Medicine (Baltimore)) - "In the use of PPIs, we should pay attention to the occurrence of related adverse reactions, especially the damage to the infection-related adverse effects, monitor the relevant indicators, and take timely intervention measures to ensure the safety of medication."

Adverse events • Journal • Gastrointestinal Disorder • Infectious Disease • Pneumonia • Respiratory Diseases

Bioequivalence of a single dose of two palbociclib formulations in healthy Chinese subjects under fasting conditions: a two-period crossover study with rabeprazole pre-treatment. (PubMed, Front Pharmacol) - P1 | "Both formulations were safe and well tolerated. http://www.chinadrugtrials.org.cn, identifier CTR20232617; https://www.chictr.org.cn, identifier ChiCTR2400084355."

Clinical • Journal

CTN-03208-1: Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=112 | Completed | Sponsor: Lomond Therapeutics Holdings, Inc. | Active, not recruiting ➔ Completed

First-in-human • Trial completion • Acute Myelogenous Leukemia

Proton pump inhibitors and the risk of urolithiasis: A Mendelian randomization study. (PubMed, Medicine (Baltimore)) - "The genome-wide association studies (GWAS) of Omeprazole, Esomeprazole, Lansoprazole, and Rabeprazole medication can be obtained from GWAS catalog. In conclusion, our results suggest a causal relationship of PPIs to UL. For patients requiring antiacid therapy, esomeprazole may be a better option than Rabeprazole, especially in patients with high-risk factors for urolithiasis."

Journal • Renal Calculi • Urolithiasis

Bismuth-Based quintuple therapy: a step beyond quadruple regimens in H. Pylori treatment and the impact of patient compliance. (PubMed, BMC Gastroenterol) - "In this study, we demonstrated that bismuth-based quintuple therapy can be used as an alternative to bismuth-based quadruple therapies and other high-risk treatments. However, we also highlighted the critical importance of treatment adherence."

Compliance • Journal • Infectious Disease

Efficacy of 10 days high-dose and double-dose rabeprazole-based concomitant therapy for Helicobacter pylori eradication among Lebanese population: a pilot randomized controlled trial. (PubMed, BMC Gastroenterol) - "The use of high-dose PPI with 10 days of concomitant therapy (Group C) demonstrated the highest eradication rate among the study groups. This promising finding suggests a potential benefit of the high-dose PPI regimen with 10-day concomitant therapy but must be interpreted with caution; it warrants further investigation in a larger and adequately powered randomized controlled trial to confirm its efficacy and generalizability, given the pilot nature of this study."

Journal • Allergy • Celiac Disease • Extranodal Marginal Zone Lymphoma • Gastric Cancer • Gastroenterology • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Oncology

Class effects of proton pump inhibitors in preventing oxaliplatin-induced peripheral neurotoxicity. (PubMed, J Pharmacol Sci) - "Basic research has revealed that omeprazole, a proton pump inhibitor (PPI), exerts preventive effects against OIPN...Notably, esomeprazole, lansoprazole, and rabeprazole, classified as PPIs, prevented oxaliplatin-induced cultured F11 neuronal cell damage, and repeated PPI administration prevented mechanical allodynia in rats. However, vonoprazan, a potassium ion-competitive acid blocker, did not exert such effects. Overall, our results highlight the class effects of PPIs against OIPN."

Journal • Pain

Innovative approaches in HELICOBACTER pylori therapy: Clinical trials and advancements in Gastro-Retentive drug delivery systems. (PubMed, Arab J Gastroenterol) - "The conventional treatment involves a triple therapy regimen combining Rabeprazole, Amoxicillin, and Clarithromycin with the effectiveness of 10-day versus 14-day courses. Further, it also includes conventional treatment, its drawbacks and alternative treatment approaches available. Additionally, it also discussed about various clinical trials that have been reported for the treatment of H. PYLORI."

Journal • Review • Anorexia • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor